Peer-led Community-based PrEP Delivery Among Youth in Brazil
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Oct 24, 2024
Trial Information
Current as of July 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on finding out how well a new approach to delivering HIV prevention medication, called PrEP, works for young sexual and gender minority individuals in Brazil. The study aims to see if having peers—other young people who identify as sexual or gender minorities—provide the PrEP medication is more effective than the usual care offered in health facilities. The trial will involve participants aged 15 to 24 who are sexually active and are not currently using PrEP.
To be eligible for this study, participants must identify as men who have sex with men or as transgender women. They should be willing to learn about PrEP and agree to be randomly assigned to either the peer-led support group or the standard care group. If you join this study, you will have the chance to receive support and information about PrEP from peers who understand your experiences. It’s a unique opportunity to be part of a community-based effort to improve health outcomes for young people like you.
Gender
ALL
Eligibility criteria
- Eligibility Criteria:
- • Aged 15-24 years
- • Candidate for HIV prevention
- • Sexually active
- • Not currently using PrEP
- • Willing to discuss oral PrEP
- • Agree to be randomized to either intervention or standard care arm
- Exclusion Criteria:
- • HIV positive test result
- • Not currently sexually active
- • Currently using PrEP
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salvador, Bahia, Brazil
São Paulo, , Brazil
Patients applied
Trial Officials
Katia J Bruxvoort, PhD
Principal Investigator
University of Alabama at Birmingham School of Public Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported